Biogen has announced it will give up ownership and halt sales of Aduhelm, an embattled Alzheimer's disease drug that was scrutinized following its 2021 approval. Biogen said it terminated a ...

Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago. The drugmaker said Wednesday ...

Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer's disease therapy lecanemab, which is now fully filed with the FDA.

In a rare – and possibly unique – turn of events, both pharmacy company Biogen and its shareholders have asked a federal ...

Biogen's hopes were for sales of around $18 billion per year from Aduhelm, says the document, without consideration of the impact that could have on the US healthcare system.

A performance analysis of the current constituents of the S&P 500 Index Over the Last 30 Years ending September 2024 ...

In the fourth quarter of 2021, for example, Aduhelm could only muster $1 million in sales. Since then, prospects for the biologic didn’t appreciably improve. The drug’s manufacturer Biogen ...

The group of $1 trillion market cap stocks is tiny, and pharmaceutical giant Eli Lilly (NYSE: LLY) isn't a member yet, though ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on BIIB stock, giving a Buy rating on September 24. Salim Syed has ...

Investors knocked Biogen stock down by more than 10% early Wednesday after the US Centers for Medicare and Medicaid Services set a limit on its coverage of Aduhelm, the company's drug to treat ...

Biogen said it is investigating the recent death of a 75-year-old patient who had taken the company’s new Alzheimer’s drug Aduhelm. Apple is working on features designed to detect depression ...